Amorphous microneedle device for drug delivery

Abstract

The utility model discloses an amorphous microneedle device for drug delivery, which comprises a needle body, the needle body is made of an amorphous alloy material, the middle part of the needle body is of a spiral shell structure, one end of the needle body is of a conical needle head structure, and the other end of the needle body is fixedly connected to a flexible substrate; the amorphous microneedle device for drug delivery is stable and reliable in mechanical and chemical performance and small in needle breaking probability, drug delivery of a corium layer and an epidermal layer can be carried out at the same time, and the utilization rate of drugs is increased.

Description

Technical Field

[0001] The utility model relates to the technical field of transdermal microneedle technology, and particularly relates to an amorphous microneedle device for drug delivery. Background Technique

[0002] As a new technology for transdermal drug delivery, microneedles (MNs) have received increasing attention and applications in recent years, and have been extended in three dimensions in the fields of medicine, diagnosis, and medical aesthetics. It mainly utilizes the property of microneedles to transdermally deliver drugs to achieve efficient and precise controlled delivery of active pharmaceutical ingredients, avoiding gastrointestinal irritation and the first-pass effect of the liver.

[0003] A microneedle array is a minimally invasive device that acts on the stratum corneum. By forming micron-sized pores on the skin surface, macromolecular drugs (>500 Da) can penetrate the barrier of the stratum corneum in the least invasive way, increasing the transdermal penetration efficiency and reaching a specific depth to exert local or systemic effects. Compared with other transdermal injection drug delivery methods, microneedles can penetrate the stratum corneum, creating instantaneous microchannels for drug transdermal penetration, thereby delivering drugs to the dermis or subcutaneous layer. At the same time, MNs drug delivery is minimally invasive, simple to operate, painless, and the drug can be controllably released. Therefore, it has broad application prospects in local or systemic skin drug delivery. MNs are usually prepared from materials such as metal, glass, silicon, and polymer, and have the disadvantages of poor biocompatibility, easy brittle fracture or bending damage. And the currently widely used microneedles also have the following problems: For the delivery of active pharmaceutical ingredients to the skin, it is usually necessary to deliver drugs to the dermis and epidermis respectively. The existing technology is to operate in the order of the epidermis first and then the dermis, which is quite time-consuming. At the same time, for microneedles coated with drugs before insertion, the hydrophilicity of their surface to water / oil-based drugs affects the adsorption amount of drugs, thus also having a certain impact on the injection effect. Summary of the Utility Model

[0004] The purpose of the utility model is to provide an amorphous microneedle device for drug delivery, which has stable and reliable mechanical and chemical properties, a small probability of broken needles, and can simultaneously deliver drugs to the dermis and epidermis, improving the utilization rate of drugs.

[0005] To achieve this purpose, the utility model adopts the following technical solutions:

[0006] Provide an amorphous microneedle device for drug delivery, including a needle body. The needle body is made of amorphous alloy material. The middle part of the needle body is a spiral shell structure. One end of the needle body is a conical needle head structure, and the other end of the needle body is fixedly connected to a flexible substrate.

[0007] As a preferred embodiment of the amorphous microneedle device for drug delivery, the needle body includes a needle head, an extension part, and a connecting part. The extension part is a spiral shell structure, the needle head is a conical structure, the needle head is arranged at one end of the extension part, and the connecting part is distributed on the outer periphery of the other end of the extension part. The extension part is fixedly connected to the flexible substrate through the connecting part.

[0008] As a preferred embodiment of the amorphous microneedle device for drug delivery, the needle body is an iron-based amorphous alloy.

[0009] As a preferred embodiment of the amorphous microneedle device for drug delivery, the material of the flexible substrate is polyimide or polyurethane.

[0010] As a preferred embodiment of the amorphous microneedle device for drug delivery, the extension part is a cylindrical structure with the same spiral outer diameter.

[0011] As a preferred embodiment of the amorphous microneedle device for drug delivery, the spiral outer diameter of the extension part gradually increases along the direction from the needle head to the connecting part, and the extension part and the needle head form a conical structure.

[0012] As a preferred embodiment of the amorphous microneedle device for drug delivery, the extension part is a cylindrical structure with the same spiral outer diameter, and the spiral outer diameter at one end of the extension part gradually decreases along the direction from the connecting part to the needle head and forms a conical structure with the needle head.

[0013] As a preferred embodiment of the amorphous microneedle device for drug delivery, the connecting part is an arc-shaped, wavy or serrated structure.

[0014] Advantages of the present utility model: The amorphous microneedle device for drug delivery proposed by the present utility model has a high corrosion resistance, good biocompatibility, stable and reliable mechanical and chemical properties, and a low probability of broken needles by setting the needle body as an amorphous alloy material. Moreover, the middle part of the needle body is a spiral shell structure, enabling the present utility model to simultaneously deliver drugs to the dermis and epidermis layers and improve the utilization rate of drugs. Further, the matching structure of the flexible substrate and the needle body makes the microneedles more conform to the curvature of the human skin when piercing the skin. Description of the Drawings

[0015] In order to more clearly illustrate the technical solutions of the embodiments of the present utility model, the drawings required to be used in the embodiments of the present utility model will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present utility model. For those of ordinary skill in the art, other drawings can be obtained based on these drawings without creative efforts.

[0016] Figure 1It is a schematic structural diagram of an amorphous microneedle device for drug delivery according to an embodiment of the present utility model;

[0017] Figure 2 It is a schematic structural diagram of an amorphous microneedle device for drug delivery according to another embodiment of the present utility model;

[0018] Figure 3 It is a schematic structural diagram of an amorphous microneedle device for drug delivery according to another embodiment of the present utility model.

[0019] In the figure:

[0020] 1. Needle body; 101. Needle head part; 102. Extension part; 103. Connection part; 2. Flexible substrate. Specific implementation manners

[0021] The following describes the embodiments of the present disclosure in detail with reference to the accompanying drawings.

[0022] The following illustrates the implementation manners of the present disclosure through specific specific examples. Those skilled in the art can easily understand other advantages and effects of the present disclosure from the content disclosed in this specification. Obviously, the described embodiments are only a part of the embodiments of the present disclosure, rather than all the embodiments. The present disclosure can also be implemented or applied through other different specific implementation manners. Various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present disclosure. It should be noted that, without conflict, the following embodiments and the features in the embodiments can be combined with each other. All other embodiments obtained by those of ordinary skill in the art based on the embodiments in the present disclosure without making creative efforts belong to the scope of protection of the present disclosure.

[0023] Referring to Figure 1 , an embodiment of the present utility model provides an amorphous microneedle device for drug delivery, including a needle body 1. The needle body 1 is made of amorphous alloy material. The middle part of the needle body 1 is a spiral shell structure. One end of the needle body 1 is a conical needle head structure, and the other end of the needle body 1 is fixedly connected to a flexible substrate 2.

[0024] Specifically, the needle body 1 includes: a needle head part 101, an extension part 102 and a connection part 103. The extension part 102 is a spiral shell structure. The needle head part 101 is a conical structure. The needle head part 101 is arranged at one end of the extension part 102. The connection part 103 is distributed on the outer periphery of the other end of the extension part 102. The extension part 102 is fixedly connected to the flexible substrate 2 through the connection part 103; wherein, the connection part 103 can be fixedly connected to the flexible substrate 2 by an embedded structure.

[0025] In the above technical solution, by setting the needle body 1 to be made of amorphous alloy, it has high corrosion resistance, good biocompatibility, stable and reliable mechanical and chemical properties, a small probability of needle breakage, and the middle part of the needle body 1 is a spiral shell structure; the spiral gap of the needle body 1 and the inside of the shell can be used to carry or fill drugs, enabling the present utility model to simultaneously perform drug delivery to the dermis and epidermis layers, improving the utilization rate of drugs; further, the matching structure of the flexible substrate 2 and the needle body 1 makes the microneedles more conform to the curvature of the human skin when piercing the skin.

[0026] In some embodiments, the needle body 1 is an iron-based amorphous alloy; specifically, such as: Fe 71-x B 22 Y6Mo X (1≤X≤10) and Fe 60 Mg 40-X Mn X (20≤X≤25), etc.

[0027] In some embodiments, the material of the flexible substrate 2 is polyimide or polyurethane. In some other embodiments, the material of the flexible substrate 2 can also be a mixture of one or more of other flexible polymers with biocompatibility.

[0028] In some embodiments, the extension part 102 is a cylindrical structure with the same spiral outer diameter; that is, a spiral structure similar to a spring. Among them, the extension part 102 can be an entire spiral shell structure; it can also be only the middle section is a spiral shell structure, and the head and tail sections are shell or solid structures.

[0029] Refer to Figure 2 , in another embodiment, the spiral outer diameter of the extension part 102 gradually increases along the direction from the needle head 101 to the connection part 103, and the extension part 102 and the needle head 101 form a conical structure.

[0030] Refer to Figure 3 , in some other embodiments, the extension part 102 is a cylindrical structure with the same spiral outer diameter, and the spiral outer diameter at one end of the extension part 102 gradually decreases along the direction from the connection part 103 to the needle head 101 and forms a conical structure with the needle head 101.

[0031] In some specific embodiments, the structure of the connection part 103 is not limited to Figure 1 the arc structure shown, and it can also adopt structures such as wavy or serrated to improve the connection stability between the connection part 103 and the flexible substrate 2 and prevent the needle body 1 from separating from the flexible substrate 2.

[0032] In the description of the present utility model, it should be understood that the orientation or positional relationship indicated by terms such as "middle", "length", "upper", "lower", "front", "rear", "vertical", "horizontal", "inner", "outer", "radial", "circumferential", etc. is based on the orientation or positional relationship shown in the drawings. It is only for the convenience of describing the present utility model and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation. Therefore, it should not be construed as a limitation to the present utility model.

[0033] In the present utility model, unless otherwise clearly specified and defined, the first feature being "on" the second feature may be that the first and second features are in direct contact, or the first and second features are indirectly in contact through an intermediate medium. The meaning of "a plurality of" is at least two, such as two, three, etc., unless otherwise clearly and specifically defined.

[0034] In the present utility model, unless otherwise clearly specified and defined, terms such as "installed", "connected", "joined", "fixed", etc. should be understood in a broad sense. For example, it may be a fixed connection, a detachable connection, or integrated; it may be a mechanical connection, an electrical connection, or communicable with each other; it may be directly connected, or indirectly connected through an intermediate medium, and may be the internal communication of two elements or the interaction relationship between two elements, unless otherwise clearly defined. For those of ordinary skill in the art, the specific meanings of the above terms in the present utility model can be understood according to specific circumstances.

[0035] The above is only for illustrating the implementation manners of the present utility model and is not used to limit the present utility model. For those skilled in the art, any modifications, equivalent replacements, improvements, etc. made without creative efforts within the spirit and principle of the present utility model shall be included within the protection scope of the present utility model.

Claims

1. An amorphous microneedle device for drug delivery, characterized in that: The needle body (1) comprises a needle body (1), wherein the needle body (1) is made of an amorphous alloy, the middle part of the needle body (1) is a spiral shell structure, one end of the needle body (1) is a conical needle head structure, and the other end of the needle body (1) is fixedly connected to a flexible substrate (2).

2. The amorphous microneedle device for drug delivery according to claim 1, characterized in that: The needle body (1) comprises: a needle head (101), an extension part (102) and a connecting part (103); the extension part (102) is a spiral shell structure; the needle head (101) is a conical structure; the needle head (101) is arranged at one end of the extension part (102); the connecting part (103) is distributed on the periphery of the other end of the extension part (102); and the extension part (102) is fixedly connected to the flexible base (2) via the connecting part (103).

3. The amorphous microneedle device for drug delivery according to claim 1, characterized in that: The needle body (1) is an iron-based amorphous alloy.

4. The amorphous microneedle device for drug delivery according to claim 1, characterized in that: The material of the flexible substrate (2) is polyimide or polyurethane.

5. The amorphous microneedle device for drug delivery according to claim 2, characterized in that: The extension portion (102) is a cylindrical structure having the same spiral outer diameter.

6. The amorphous microneedle device for drug delivery according to claim 2, characterized in that: The spiral outer diameter of the extension portion (102) gradually increases along the direction from the needle head (101) to the connecting portion (103), and the extension portion (102) and the needle head (101) form a conical structure.

7. The amorphous microneedle device for drug delivery according to claim 2, characterized in that: The extension portion (102) is a columnar structure with the same spiral outer diameter, and the spiral outer diameter at one end of the extension portion (102) gradually decreases along the direction from the connecting portion (103) to the needle head (101), and forms a conical structure with the needle head (101).

8. The amorphous microneedle device for drug delivery according to claim 2, characterized in that: The connecting portion (103) is an arc-shaped, wave-shaped or sawtooth-shaped structure.

Images